

This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.



June 26, 2025

Company name:	Kaneka Corporation
Representative:	Kazuhiko Fujii, President, Representative Director
Listing:	Prime Market, Tokyo Stock Exchange
Securities code:	4118
Inquiries:	Atsuya Inoguchi, Head of Investors Relations Department (Tel 03 – 5574 - 8090)

**(Correction) Notice Concerning Partial Correction of
“Financial Summary for the Fiscal Year Ended March 31, 2025”**

Kaneka Corporation hereby announces that there was an error in a part of the “Financial Summary for the Fiscal Year Ended March 31, 2025,” disclosed on May 15, 2025, as detailed below.

Revised materials reflecting the corrected information have been posted on our corporate website (<https://www.kaneka.co.jp/en/ir/library/briefs/>).

Notice

I. Details of Correction

Corrections are outlined in red.

[Before Correction]

Page 11



Investment, Depreciation, R&D Expenses

	(Billions of yen)		
	FY2023	FY2024	Difference
Capital investment	69.2	53.1	(16.1)
Depreciation and amortization	40.5	43.6	3.1
R&D expenses	35.4	39.8	4.4
R&D expenses to net sales	4.6%	4.9%	

● Main capital investment

FY2024 Results

- Introduction of co-generation system at Takasago
- Construction of new plant for blood purification devices and catheter in Hokkaido (Tomato Manufacturing Site)
- Increased production capacity in Kaneka Belgium N.V., MS

©2025 Kaneka Group All rights reserved. 11

[After Correction]

Page 11



Investment, Depreciation, R&D Expenses

	(Billions of yen)		
	FY2023	FY2024	Difference
Capital investment	69.2	53.1	(16.1)
Depreciation and amortization	40.5	43.6	3.1
R&D expenses	35.4	39.3	3.9
R&D expenses to net sales	4.6%	4.9%	

● Main capital investment

FY2024 Results

- Introduction of co-generation system at Takasago
- Construction of new plant for blood purification devices and catheter in Hokkaido (Tomato Manufacturing Site)
- Increased production capacity in Kaneka Belgium N.V., MS

©2025 Kaneka Group All rights reserved. 11

The revision is due to a misclassification between R&D expenses and selling expenses within SG&A. This has no impact on operating income or subsequent profit figures, nor does it affect the profit and loss results by business segment.